Cheshire, United Kingdom

Adrian Liam Gill

This inventor holds 15 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Astex Therapeutics Limited, Cancer Research Technology Limited, The Institute of Cancer Research: Royal Cancer Hospital. Active years: 2008-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adrian Liam Gill. Retrieved from https://idiyas.com/inventor/adrian-liam-gill

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15 

% Patents Active = 20.0


 

Average Co-Inventor Count = 8.8

ph-index = 6

Forward Citations = 170(Granted Patents)


Location History:

  • Caldecote, GB (2008)
  • Cambridge, GB (2011)
  • Macclesfield, GB (2009 - 2014)
  • Buxton, GB (2012 - 2014)
  • Cheshire, GB (2010 - 2015)

Company Filing History:


Years Active: 2008-2015

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Cyclin Dependent Kinase
Glycogen Synthase Kinase-3
FGFR Inhibitors
Pyrazole Compounds
Imidazo Compounds
Benzimidazole Derivatives
Therapeutic Compounds
Protein Kinase Inhibitors
Pharmacophore Compounds
Cancer Treatment
15 patents (USPTO):Explore Patents

Title: The Innovations of Adrian Liam Gill

Introduction: Adrian Liam Gill is an esteemed inventor based in Cheshire, Great Britain, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 15 patents, Gill's work primarily focuses on the development of compounds that address critical medical conditions, particularly cancers.

Latest Patents: One of Adrian Liam Gill's latest patents is for 3,4-disubstituted 1H-pyrazole compounds, which serve as modulators for cyclin-dependent kinase and glycogen synthase kinase-3. This invention provides innovative compounds designed for the prophylaxis and treatment of disease states, especially cancers that are mediated by these crucial kinases. Another recent patent revolves around bicyclic heterocyclic compounds identified as FGFR inhibitors, which include new derivatives for pharmaceutical compositions aimed at treating various diseases, including cancer.

Career Highlights: Throughout his career, Adrian has made notable strides while working with respected organizations. His tenure at Astex Therapeutics Limited and Cancer Research Technology Limited highlights his commitment and expertise in drug discovery and development. These positions have allowed him to refine his skills and contribute to groundbreaking advancements in the pharmaceutical industry.

Collaborations: In his innovative journey, Adrian has collaborated with prominent figures such as Valerio Berdini and Maria Grazia Carr. These partnerships have fostered a collaborative environment that emphasizes the importance of teamwork in achieving significant technological advancements.

Conclusion: Adrian Liam Gill's contributions to the field of pharmaceuticals through his patents are pivotal in the fight against cancer and other diseases. His dedication and innovative spirit continue to inspire future generations of inventors and researchers in the pursuit of advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…